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Summary 
It has been reported previously that antitumor cytolytic T lymphocyte (CTL) clones can be isolated 
from blood lymphocytes of HLA-A2 melanoma patients, after stimulation in vitro with autologous 
tumor cells, and that some of these CTL clones lyse most HLA-A2 melanomas. A first antigen 
recognized by such CTL clones was previously shown to be encoded by the tyrosinase gene. 
We report here the identification of another gene that also directs the expression of an antigen 
recognized on most  melanomas by CTL  clones that  are restricted by HLA-A2.  The  gene, 
designated Melan-A, is unrelated to any known gene. It is 18 kb long and comprises five exons. 
Like the tyrosinase gene, it is expressed in most melanoma tumor samples and, among normal 
cells,  only in melanocytes. 
W 
hen blood  lymphocytes of melanoma patients  are 
stimulated in vitro with autologous tumor cells in 
the presence of IL-2, one often observes proliferation of re- 
sponder cells that exert a cytolytic activity on the tumor cells. 
From these responder cells it has been possible to obtain clones 
of cytolytic T lymphocytes (CTL) 1, that lyse the autologous 
melanoma cells but do not recognize autologous fibroblasts, 
EBV-transformed autologous B cells, or targets ceils that are 
lysed by NK-like effectors (1-5). Several groups have derived 
from HLA-A2 melanoma patients CTL that lyse not only 
the autologous tumor ceils but also a large proportion of the 
melanoma cell lines derived from other HLA-A2 patients 
(6-9).  Such CTL have been derived from both blood cells 
and from tumor-infiltrating lymphocytes. 
By immunoselection with CTL clones derived from blood 
lymphocytes of patient SK29(AV), two distinct antigens were 
described that were shared by a high proportion of HLA-A2 
melanomas. The antigens were named SK29-Aa and SK29- 
Ab (9). The latter is encoded by the tyrosinase gene, which 
is expressed only in melanocytes and melanomas (10). 
We report here the identification of a second gene that 
codes for antigen SK29-Aa.  The cloning approach involved 
1 Abbreviation used in this paper: CTL, cytolytic  T lymphocyte. 
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the transfection of a cDNA library in COS cells, which are 
monkey kidney cells transfected with the gene coding for the 
SV40 large T  antigen (11, 12). When these cells are trans- 
fected with plasmids containing the SV40 origin of replica- 
tion, these plasmids replicate so as to produce 104-10  s copies 
per cell (13),  resulting in a high level of expression of the 
cloned cDNA.  Our data suggest that transfecting cDNA 
libraries into  COS cells will be widely applicable for the 
identification of antigens recognized by T  lymphocytes. 
Materials and Methods 
Cell Lines.  Tumor cell lines LB39-MEL and LB33-MEL were 
derived from the metastatic melanomas of patients LB39 and LB33, 
respectively. The melanoma cells were cultured in Iscove's medium 
supplemented with 10% FCS (both from GIBCO BRL, Gaithers- 
burg, MD), r-arginine (116 rag/liter), t-asparagine (36 mg/liter), 
and r-glutamine  (216 mg/liter). Melanoma cell lines SK29-MEL 
and SK23-MEL, and melanocyte samples, were gifts from Dr. L. 
Old (Memorial Sloan-Kettering Cancer Center, New York). SK29- 
MEL was cloned by limiting dilution and clone SK29-MEL.I was 
selected for further experiments (9,  14). The obtention of the 
antigen-loss variants of  SK29-MEL has been described  (9, 15). Mela- 
noma cell line NA8-MEL was a gift from Dr. F. Jotereau (INSERM 
Unit~ 211, Nantes, France). SK29-MEL, SK23-MEL and NA8-MEL 
cells were cultured in DMEM (GIBCO BILL) containing 10% FCS, 
University Press ￿9 0022-1007/94/07/0035/08 $2.00 10 mM Hepes and 4.5 g/liter glucose. COS-7 cells (American Type 
Culture Collection CRL 1651; Rockville, MD) were cultured in 
DMEM containing 10% FCS. WEHI-164 clone 13 (W13), a gift 
of Dr. T. Espevik (University of Trondheim, Trondheim, Norway; 
16), was cultured in RPMI-1640 (GIBCO BRL) supplemented with 
5%  FCS. 
Derivation and Culture of CTL Clones.  Mixed lymphocyte-tumor 
cultures of PBL and tumor cells isolated from patient LB39 were 
performed as previously described (4) except that the medium was 
supplemented with 5 U/ml of human recombinant Ib-4 (a gift from 
R. Devos, Roche Research, Gent, Belgium).  Derivation, long-term 
culture, and specificity analysis of CTL clones from PBL of patient 
SK29(AV) were previously described (9,  15). 
Assay for Cytolytic Activity.  The protocol was  previously de- 
scribed  (4).  Target cells were treated for 48 h with 50 U/ml of 
human recombinant IFN-y (Boehringer Mannheim, Mannheim, 
Germany). CTL and 1,000 SlCr-labeled targets were incubated at 
various ratios in V-bottom microwells  in a final volume of 200 #1. 
Chromium release in the supernatant was measured after 4 h of 
incubation. 
Construction of  the cDNA Library.  Total RNA was isolated from 
clone SK29-MEL.1  and poly(A) § RNA was prepared by oligo-dT 
binding (mRNA purification kit; Pharmacia Fine Chemicals,  Pis- 
cataway, NJ). mRNA was converted to cDNA, ligated to EcoRl 
adaptors,  and inserted into  the EcoRI site  of expression vector 
pcDNAI/Amp (lnvitrogen Corporation, Oxon, UK) as described 
in the SuperScript plasmid system kit (GIBCO BRL). Recombinant 
plasmids  were electroporated into JM101 Escherichia coli bacteria 
with a Genepulser (Bio-rad Laboratories, Richmond, CA) at 1 pulse 
at 25/xF and 2,500 V, that were selected with ampicillin (50/~g/ml). 
Plasmid  DNA  from pools of bacteria was  prepared as follows. 
Titrated suspensions  of bacteria were seeded at 50, 100, or 150 bac- 
teria per well in U-bottom microwells in 0.3 ml of tryptose, yeast 
extract, glycerol, phosphate,  nitrate (TYGPN) medium (17).  10 
microplates of each dilution were prepared. Bacteria were cultured 
for 48 h at 37~  Control aliquots were titrated on agar, and only 
the set of microcultures containing close to 100 colonies per well 
were kept for the DNA extraction. Plasmid  DNA was prepared 
in the microplates by the alkaline lysis method as described (17). 
The isopropanol-precipitated DNA were resuspended in 50/~1 of 
Tris 10 mM, EDTA1 mM, pH 7.4, containing 20 ng/ml of RNase. 
Transfection of COS-7 Cells and Screening of Transfectants.  DNA 
from  pools  of bacteria  was  transfected by the  DEAE-dextran- 
chloroquine method into COS-7 cells basically as described by Arufro 
(17). 1 d before transfection, COS cells were seeded in flat-bottom 
tissue culture microwells at 15,000 cells per well in 100/~1 of DMEM 
containing 10% FCS. For transfection, medium was discarded and 
replaced by 30/~1 of DEAE-Dextran/DNA  mixtures. These mix- 
tures  were  prepared  for  duplicate  transfections  in  V-bottom 
microwells  by adding sequentially: 25 #I of plasmid DNA from 
the cDNA library,  5/xl of Tris 10 raM,  EDTA  1 mM, pH 7.4, 
containing 200 ng of plasmid pcDNAI/AmlYA2 (plasmid pcDNAI/ 
Amp containing the HLA-A2.1  gene isolated  from a CTL clone 
of patient SK29 [9]), 5/~1 of DMEM-NS (DMEM medium sup- 
plemented with 10% decomplemented NuSerum IV [Collabora- 
tive Biomedical Products, Bedford, MA D, and 35/~1 of DMEM- 
NS supplemented with 0.8 mg/ml DEAE-Dextran (Pharmacia) and 
200 #M chloroquine. The COS cells were incubated for 4 h at 
37~  DEAE-Dextran/DNA  was discarded and replaced by 50 #1 
of PBS containing 10% DMSO. After 2 min at room temperature, 
PBS-DMSO was replaced by 200/~1 of DMEM supplemented with 
10% FCS. Transfected COS cells were incubated for 48 h at 37~ 
The medium was then discarded and 1,000-2,000 CTL were added 
in 100/xl of Iscove's medium containing 10% human serum and 
25 U/ml IL-2 (a gift of Biogen, Geneva, Switzerland). After 24 h, 
the supernatant was collected and its TNF content was determined 
by its cytolytic effect on WEHI-164 clone 13 cells (W13) (16) as 
previously described  (18). 
Analysis of the Structure of Gene Melan-A.  A genomic library 
of 700,000 independent cosmids was constructed in cosmid c2RB 
with DNA from melanoma cell line LB33-MEL as described (19). 
Southern blots were prepared with DNA isolated from 22 groups 
of 70,000  cosmids.  32P-labeled eDNA clone AaG1 hybridized to 
nine groups. The group that produced the strongest hybridization 
band was  subcloned, and a cosmid that contained the Melan-A 
sequence was identified by colony hybridization with the labeled 
eDNA. The cosmid was sequenced  using primers deduced from 
the sequence of eDNA  AaG1,  using the Cycle-Sequencing Kit 
(United  States  Biochemical  Corp.,  Cleveland,  OH).  Complete 
sequences were obtained for introns 1, 2, and 4, and for the 3' and 5' 
ends of intron 3. The size of intron 3 was estimated as follows. 
Southern blots were prepared with cosmid DNA digested with 
EcoRI  and  Bgl  II.  A  7-kb  EcoRl  fragment  hybridized  with 
32P-labeled oligonucleotides deduced from the sequences of both 
ends ofintron 3. The computer search for sequence homology was 
done with program FASTA on GenBank database  release 79.0. 
Transfection of  a Melanoma Cell Line.  Melanoma line NA8-MEL 
was transfected by the calcium  phosphate precipitation method, 
as described  (18). Briefly, 7.5  x  10  s cells were seeded in 4.5 ml 
of medium. 24 h later, they were transfected with 2 pg of plasmid 
pSVtkneo3 and 20/~g of plasmid pcDNAI/Amp containing eDNA 
AaG1. After 48 h, the cells were seeded in microcultures at 2,000 
cells/well in 200 #1 of medium containing 2 mg/ml of neomycin 
analog G418 (GIBCO BRL). NeoR colonies were selected for fur- 
ther experiments. 
PCR Assays for Melan-A Expression.  Isolation of total RNA 
from tumor samples was performed as described (20). RNA from 
melanocyte culture was a gift from Dr. Old. Reverse transcription 
was performed on 2 pg of total RNA with an oligo(dT) primer. 
eDNA corresponding to 100 ng of total RNA  (104 cell equiva- 
lents)  was  amplified  for 33  cycles by PCR  with  the following 
primers:  sense  5'-ACTGCTCATCGGCTGTTG-3',  antisense 
5'-TCAGCCATGTCTCAGGTG-Y. These primers are located in 
exons 2 and 5 to exclude the amplification of genomic DNA. An 
aliquot of the PCR reaction was run on a 1% agarose gel stained 
with ethidium bromide. To ensure that the RNA were not degraded, 
the eDNA products were tested for the presence of human 3-actin. 
Results 
Blood lymphocytes of HLA-A2 melanoma patient LB39 
were stimulated in vitro with irradiated cells of autologous 
tumor cell line LB39-MEL. From the responder T cell popu- 
lation,  we isolated cytolytic T  cell clone LB39-CTL-1/95, 
which lysed the autologous melanoma cell line (Fig. 1). This 
CTL clone also lysed melanoma cells from several other HLA- 
A2 melanoma patients, suggesting that its target antigen was 
presented by HLA-A2 (Fig.  1). This was confirmed by the 
observation that a previously described cell variant of mela- 
noma line SK29-MEL that had lost HLA-A2 was not lysed 
by CTL  1/95  (Fig.  1). 
The  antigen  recognized  by  CTL  1/95  appeared  to  be 
different from the previously described melanoma  antigen 
SK29-Ab, which is encoded by tyrosinase, because an antigen- 
loss variant of SK29-MEL, which was resistant to antityros- 
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(anti-tyrosinase)  Figure  1.  Lysis  by CTL clone LB39-CTL-1/95 of autolo- 
gous melanoma LB39-MEL, HLA-A2 allogeneic melanoma 
SK23-MEL, and variants of allogeneic melanoma SK29-MEL. 
One variant, named 29.1.5.86, had been selected for resis- 
tance to an antityrosinase CTL, whereas the other, named 
29.1.22, had lost expression  of HLA-A2. Antityrosinase  CTL 
SK29-CTL-IVSB was tested on the same targets. 
inase CTL clone SK29-CTL-IVSB,  was still lysed by CTL 
1/95 (Fig.  1). The target antigen of CTL 1/95 was named 
LB39-Aa. When CTL 1/95 was tested on other antigen-loss 
variants obtained from melanoma SK29-MEL, it showed the 
same  lytic  pattern  as  CTL  clones  obtained  from  patient 
SK29(AV)  that  recognize an antigen described as SK29-Aa 
(9). This suggested that antigen LB39-Aa was the same an- 
tigen as SK29-Aa. 
Identification of  a cDNA Coding  for Antigen LB39-Aa.  Be- 
cause melanoma line SK29-MEL was lysed by CTL  1/95, 
we used a cDNA library that had been prepared with KNA 
from this cell line.  This library had been prepared with ex- 
pression vector pcDNAI/Amp. This vector carries the SV40 
origin of replication which enables it to replicate autonomously 
in COS cells to large copy numbers (13).  This library was 
divided into  800 pools of 100 bacteria.  Each pool was ex- 
pected to contain approximately 25 different cDNAs because 
only 50% of the plasmids contained an insert and the cloning 
was not directional.  The HLA-A2.1 gene of patient SK29(AV) 
was also cloned into plasmid pcDNAI/Amp. 
Each cDNA pool was cotransfected with the HLA-A2 con- 
struct into duplicate microcultures of COS-7 cells. After 48 h, 
the transfected COS cells were tested for expression of an- 
tigen LB39-Aa by their ability to stimulate the production 
of TNF by CTL 1/95. The CTL were added to the transfec- 
tants and after 24 h the concentration of TNF in the culture 
supernatant was measured by its cytotoxic effect on W13 cells. 
The  amounts  of TNF  found in the  supernatant  showed a 
wide variation ranging from 2 to 7 pg/ml in most microcul- 
tures (Fig.  2). Six values stood out above 8 pg/ml.  Among 
those we found two pairs of high duplicates. From each of 
the two pools of bacteria corresponding  to these duplicate 
positives, we subcloned 800 bacteria. Plasmid DNA was ex- 
tracted from each of the 1,600 bacteria and cotransfected into 
COS cells with the HLA-A2 construct.  One clone, named 
AaG1, was found to confer recognition by CTL 1/95: COS 
cells transfected with this cDNA clone stimulated TNF re- 
lease by the CTL (Fig. 3). They also stimulated CTL clone 
SK29-CTL-10/196, an HLA-A2-restricted CTL known to 
recognize on SK29-MEL the SK29-Aa antigen (9) (Fig.  3). 
The antityrosinase CTL IVSB was not stimulated by COS 
cells  transfected with  cDNA AaG1  (Fig.  3). 
Stable transfectants were made in order to confirm the results 
obtained with COS cells. We used HLA-A2 melanoma cell 
line NAS-MEL which was not recognized by anti-Aa CTL 
1/95. The cells were cotransfected with the pcDNAI/Amp 
plasmid containing cDNA AaG1 and with a plasmid confer- 
ring resistance to geneticin.  Clones were isolated from the 
geneticin-resistant transfectants.  They proved sensitive to lysis 
by CTL 1/95 (Fig. 4 A) and they also stimulated the produc- 
tion  of TNF by this  CTL  (Fig.  4 B). 
Structure of the Gene Coding for Antigen LB39-Aa.  The 
sequence of cDNA clone AaG1  proved to be 675-bp long. 
When a Northern blot prepared with RNA of melanoma 
cell line SK29-MEL was hybridized with this cDNA, a band 
of ",,0.75  kb was observed, suggesting that clone AaG1 was 
incomplete.  It was used to screen  again the cDNA library 
derived from SK29-MEL and a cDNA clone of 760 bp, named 
Aa84/3, was obtained. This cDNA clone was strictly iden- 
tical to AaG1 except for the addition of 85 bp at the 5' end. 
The sequence of cDNA Aa84/3 is shown on Fig. 5. No 
significant homology with any gene recorded in data banks 
was observed. The putative protein comprises 118 amino adds. 
It has no signal sequence. It is rich in proline residues (9%) 
and contains a hydrophobic region spanning residues 27-48 
(Fig.  5). 
To isolate the gene corresponding to cDNA AaG1, DNA 
was prepared from 22 groups of 70,000 cosmids of a human 
genomic library. The cDNA hybridized to nine cosmid groups. 
We subcloned the group that produced the strongest hybrid- 
ization band and we identified one cosmid that  hybridizes 
with cDNA clone AaG1. Genomic sequences corresponding 
to exons and adjacent intron regions were obtained by se- 
quencing the cosmid with primers deduced from the cDNA 
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Figure  2.  Stimulation of CTL 1/95 by COS cells cotransfected with HLA-A2 and pools of approximately  25 different cDNAs obtained from mela- 
noma cell SK29-MEL.  Each symbol represents  the TNF content of one individual  microculture,  and the duplicate  microplates  are named A and A', 
B and B', etc. Duplicates  of seemingly positive microcuhures are connected with a line. Each pool of cDNAs was transfected into duplicate microcultures. 
Both the HLA-A2 gene and the cDNAs were cloned into expression vector pcDNAl/Amp. They were cotransfected with DEAE-Dextran into subconfluent 
COS cells: 48 h after transfection,  CTL 1/95 (2,000 cells per well) was added,  The culture supernatants  were harvested  1 d later and tested on W13 
cells for their TNF content. 
sequence. The comparison of the cosmid and cDNA sequences 
indicated  that  gene Melan-A  comprises  five exons  (Figs.  5 
and 6). Further intron sequences were obtained using primers  .~. 
deduced from the first  sequences.  This led to the complete  ~, 
sequence of introns 1 (1,512 bp), 2 (5 kb), 4 (1,462 bp), and 
a partial  sequence of intron 3  (Fig.  6).  By hybridizing re-  ~- 
striction fragments of the cosmid with oligonucleotides cot- 
Targets: NA8-MEL 
control  +cDNA AaG  1 
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Figure  3.  Stimulation of CTL  1/95  by COS cells transfected  with 
pcDNAI/Amp constructs containing HLA-A2 and cDNA AaG1 as de- 
scribed in Materials and Methods. Control stimulator cells included HLA-A2 
melanoma SK29-MEL and COS cells transfected with HLA-A2 alone. The 
transfectants also stimulated  HLA-A2-restricted CTL clone 10/196 of  pa- 
tient SK29, which has been previously found to be directed  against  an- 
tigen LB39-Aa, and  did not stimulate  antityrosinase  CTL clone SK29- 
CTL-IVSB. 
Figure  4.  Recognition of antigen LB39-Aa expressed in a transfectant 
obtained by cotransfecting  HLA-A2 melanoma cell line NA8-MEL with 
the pcDNAI/Amp-cDNA AaG1 construct and pSVtkneofl. (A) Lysis of 
geneficin-resistant transfectant clone NA8-MEL.cl.1 by anti-LB39-Aa CTL 
1/95.  (B)  Production  of TNF  by  CTL  1/95  stimulated  with  clone 
NAS-MEL.cl.1. 
38  Tumor Rejection Antigen on HLA-A2 Melanomas ~  ..CCG 
TCAGAAATCTAAACCCGTGACTATCATGGGACTCAAAACCAGCCCAAAAAATAAG 
TCAAAACGATTAAGAGCCAGAGAAGCAGTCTTCATACACGCGGCCAGCCAGCAGA 
CAGAGGACTCTCATTAAGGAAG,.  @.,GTGTCCTGTGCCCTGACCCTACAAG 
ATG  CCA  AGA  GAA  GAT  GCT  CAC  TTC  ATC  TAT  GGT  TAC  CCC  AAG 
Met  Pro  Arg  Glu  Asp  Ala  His  Phe  Ile  Tyr  Gly  Tyr  Pro  Lys 
AAG  GGG  CAC  GGC  CAC  TCT  TAC  ACC  ACG  GCT  GAA  GA..  ~..G 
Lys  Gly  His  Gly  His  Set  Tyr  Thr  Thr  Ala  Glu  GIu 
GCC  GCT  GGG  ATC  GGC  ATC  CTG  ACA  GTG  ATC  CTG  GGA  GTC  TTA 








CTG  CTC  ATC  GGC  TGT  TGG  TAT  TGT  AGA  AGA  CGA  AAT  GGA  TAC  322 
Leu  Leu  Ile  Gly  Cys  Trp  Tyr  Cys  Arg  Arg  Arg  ASh  Gly  Tyr 
AGA  GCC  TTG  ATG..  (~..  GAT  AAA  AGT  CTT  CAT  GTT  GGC  ACT  358 
Arg  Ala  Leu  Met  Asp  Lys  Ser  Leu  His  Val  Gly  Thr 
CAA  TGT  GCC  TTA  ACA  AGA  AGA  TGC  CCA  CAA  GAA  GGG  TTT  GAT  400 
Gin  Cys  Ala  Leu  Thr  Arg  Arg  Cys  Pro  Gln  Glu  Gly  Phe  Asp 
CAT  CGG  GAC  AGC  AAA  GTG  TCT  CTT  CAA  GAG  AAA  AAC  TGT  GAA  442 
His  Arg  Asp  Ser  Lys  Val  Ser  Leu  Gln  Glu  Lys  Asn  Cys  Glu 
CCT  GTG..  (~,.  GTT  CCC  AAT  GCT  CCA  CCT  GCT  TAT  GAG  AAA  478 
Pro  Val  Val  Pro  ASh  Aia  Pro  Pro  Aia  Tyr  Glu  Lys 
CTC  TCT  GCA  GAA  CAG  TCA  CCA  CCA  CCT  TAT  TCA  CCT  TAA  517 
Leu  Ser  Ala  Glu  Gln  Ser  Pro  Pro  Pro  Tyr  Ser  Pro  OCH 
GAGCCAGCGAGACACCTGAGACATGCTGAAATTATTTCTCTCACACTTTTGCTTG  572 
AATTTAATACAGACATCTAATGTTCTCCTTTGGAATGGTGTAGGAAAAATGCAAG  627 
CCATCTCTAATAATAAGTCAGTGTTAAAATTTTAGTAGGTCCGCTAGCAGTACTA  6  8 2 
ATC  ATGTGAGGAAATGATGAGAAATATTAAAT  TGGGAAAAC TC  CAT  J--~-~TG  737 
TTGCAATGCA~CAT~.~A~  7  60 
Figure 5.  Sequence of the five exons of gene Melan-A and sequence 
of the protein encoded by the longest open reading frame. The nueleotide 
indicated as the first in exon 1 corresponds to the 5' end of eDNA clone 
Aa84/3. Box shows a polyadenylation site. A hydrophobic stretch of the 
protein  is underlined.  The  eDNA  sequence data  are  available from 
EMBL/GenBank/DDBJ  under accession number HSU06654. 
responding to each intron, a restriction map of the gene was 
obtained. An EcoKI fragment of 7 kb hybridized with oli- 
gonucleotides at the 5' and 3' sides of the partially sequenced 
intron 3 (Fig. 6). This allowed us to estimate the size of in- 
tron 3 at 9.5 kb. We concluded from these data that gene 
Melan-A has a length of ,'~18.5 kb. 
Expression of Gene Melan-A.  The pattern of expression 
of gene Melan-A was analyzed by reverse transcription and 
PCR  amplification of RNA  prepared from various  cells 
(Table 1). All of 26 melanoma tumor samples were positive. 
Among 21 melanoma cell lines we found 12 positives.  No 
expression was found in tumor samples of other histological 
types. Among normal tissues, gene Melan-A was expressed 
only by melanocytes. Among skin biopsies some scored posi- 




Mdanocytes  2/2 
Skin  2/3 
Liver  0/1 
Kidney  0/1 
Heart  0/1 
Prostate  0/1 
Breast  0/4 
Ovary  0/1 
Testis  0/2 
Adrenals  0/3 
Lung  0/2 
Fetal brain  0/1 
Cerebellum  0/1 
Substantia nigra  0/1 
Tumors 
Melanoma samples  26/26 
Melanoma cell lines  12/21 
Breast tumor samples  0/5 
Sarcoma samples  0/5 
Non  small cell lung tumor samples  0/5 
Renal carcinoma samples  0/4 
Colon carcinoma samples  0/4 
The expression of gene Melan-A was tested by reverse transcription and 
specific PCK amplification. The melanoma samples and cell lines were 
derived from a random sampling of HLA-A2 and non HLA-A2 patients. 
The amount of PCIL product did not vary significantly among the posi- 
tive samples. All KNAs presented here showed similar amplification of 
the B-actin cDNA. 
tive, presumably because they contained a higher proportion 
of melanocytes. 
Discussion 
Both the tyrosinase gene (10) and the Melan-A gene (this 
report)  have been identified as genes coding for antigens 
recognized by autologous CTL on mdanoma cells, using a 
procedure that involves high level transient expression of 
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Figure 6.  Structure of gene Melan-A with 
the exons represented as black boxes. (Stippled 
line) Part of intron 3 that was not sequenced. 
(Unfilled arrows) EcoRI restriction sites. 
39  Coulie et al. from the cosmid transfection approach that led to the iden- 
tification of gene MAGE-1, which codes for tumor antigen 
MZ2-E (21). The cDNA-COS cell approach  is  definitely 
faster and more convenient than the cosmid approach. Re- 
cently, it has led to the identification of two additional genes 
that code for human tumor antigens recognized by autolo- 
gnus CTL  (van der Bruggen, P.,  and B.  Van den Eynde, 
personal  communication). Moreover,  we have carried out 
cloning experiments  with a cDNA library of tumor MZ2-MEL, 
which expresses antigen MZ2-E.  The cotransfection  of the 
gene of HLA-A1, which is the presenting molecule, and of 
pools of the cDNA library led to the identification of several 
MAGE-1 cDNA clones. We therefore believe  that this method 
will prove widely applicable for the identification  of genes 
coding for antigens recognized by T lymphocytes.  Besides 
its convenience, the COS-cDNA approach does not require 
the obtention of antigen-loss variants, whereas for the cosmid 
approach,  these variants must be obtained to serve as trans- 
fection recipients. On the other hand, the COS-cDNA ap- 
proach requires the prior cloning of the relevant HLA gene, 
which must be cotransfected into the COS cells. 
The considerable episomal multiplication of the transfected 
plasmids generates a large amount of both the HLA mole- 
cules and the proteins encoded by the transfected  cDNA clones. 
This probably has positive and negative consequences. On 
the positive side, the expression at the cell surface of a high 
copy number of a given HLA-peptide complex may be the 
only way to identify genes coding for antigens recognized 
by CTL of relatively low affinity. Differentiation antigens 
expressed by few cells throughout the body,  such as those 
encoded by tyrosinase and Melan-A,  may fall in this cate- 
gory because high affinity T cells may have been eliminated 
by tolerance, whereas low affinity T cells may have been spared. 
On the negative side, we find that a number of antitumor 
CTL clones produce a significant level of TNF upon incuba- 
tion with COS cells transfected with the HLA gene only. 
For some CTL clones this background TNF production is 
very low. But CTL clone LB39-CTL-1/95,  which was used 
to identify gene Melan-A, produced a few picograms per mil- 
liliter of TNF when incubated  with COS cells transfected 
with a plasmid containing the HLA-A2 gene. This accounts 
for the high background displayed in Fig. 2. These crossreac- 
tions are probably a consequence of the high expression of 
the HLA molecules, some of which presumably present pep- 
tides derived from proteins  of the COS cells that resemble 
the original  antigenic peptide recognized by the CTL. 
Another drawback of the COS-cDNA cloning procedure 
seems to be the identification of inappropriate cDNA clones. 
We have described a CTL clone that recognizes an antigen 
restricted  by HLA-A2 on the autologous lung tumor cell 
line. Using the COS-cDNA method, we isolated a cDNA 
clone (2C6)  that transferred  the expression of the antigen 
into COS cells (22). We have now identified another cDNA 
clone, whose sequence is unrelated to that of cDNA clone 
2C6, and which also transfers the expression of the antigen 
into COS cells. Clearly, at least one of the two cDNA does 
not represent the appropriate gene, but codes for a peptide 
that shows enough similarity  to the appropriate  antigenic 
peptide, so that its presentation in high number by the COS 
cells stimulates the CTL clone. It will therefore be impor- 
tant to verify that cDNA clones that putatively code for an 
antigen can also confer recognition by the appropriate CTL 
when incorporated into stable transfectants that express a stan- 
dard amount of the message. This has been observed both 
with tyrosinase and the Melan-A gene reported here. But 
in our view, the definitive evidence that the pertinent gene 
has been identified would be the observation that Southern 
blots prepared with the DNA of an antigen-loss variant show 
the loss of a band that is present in the original tumor cell 
when hybridized  with the putative  cDNA. 
The Melan-A gene is the third gene that we have found 
to code for an antigen recognized on human tumors by au- 
tologous CTL. The first was gene MAGE-1 (21). It is silent 
in normal tissues except in testis and it is expressed by a 
significant proportion of tumors of different types: 40% of 
melanoma samples, 30% of lung tumors (23), and 20%  of 
breast tumors (24). The second was the tyrosinase gene (10). 
Like the Melan-A gene, it is expressed only in melanocytes 
and in melanocytic tumors. Thus both antigen SK29-Ab, 
which  is  encoded by  the  tyrosinase  gene,  and  antigen 
SK29/LB39-Aa, which is encoded by the Melan-A gene, are 
melanocytic differentiation antigens. A third differentiation 
antigen recognized by CTL on HLA-A2 melanomas was re- 
cently shown to be encoded by a cDNA coding for melano- 
cyte lineage-specific antigen gpl00 (25). The identification 
of these melanocytic differentiation antigens provides a basis 
for the observations of several groups that described antitumor 
CTL that recognized the autologous HLA-A2 melanoma cells 
as well as most melanomas derived from other HLA-A2 pa- 
tients (5-9).  Not surprisingly, CTL clones of this type have 
been shown to recognize A2 melanocytes as well (26). We 
have obtained HLA-A2-restricted  antimelanoma CTL clones 
that recognize allogeneic melanoma lines that express nei- 
ther the tyrosinase  gene, nor the Melan-A and the gpl00 genes. 
It is therefore very likely that other genes whose expression 
is restricted to the melanocytic  cell lineage also direct the ex- 
pression of antigens recognized by T  lymphocytes. 
The observation that proteins are specific for the melano- 
cytic differentiation can provide target antigens for antitumor 
CTL responses in melanoma patients is in line with previous 
observations that sera of some melanoma patients  contain 
antibodies against melanocyte differentiation antigens such 
as melanoma antigen gp75  (27, 28). 
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